General
Preferred name
TOLBUTAMIDE
Synonyms
HLS 831 ()
Tolbutamide?(HLS 831) ()
TOLBUTAMIDE SODIUM ()
Tolbutamide ()
Ipoglicone ()
Tolbutamidum ()
Willbutamide ()
Butamide ()
Pramidex ()
NSC-87833 ()
1-butyl-3-(p-tolylsulfonyl)urea ()
Glyconon ()
Rastinon ()
NSC-23813 ()
Orinase ()
Tolbutamida ()
Arkozal ()
Diabetamid ()
Tolbutamide sodium salt ()
TOLBUTAMIDE SODIUM, STERILE ()
Sodium tolbutamide ()
Orinase Diagnostic ()
Tolbutamide Sodium ()
Tolbutamide-d9 ()
P&D ID
PD001726
CAS
64-77-7
473-41-6
100735-34-0
1219794-57-6
Tags
available
drug
Approved by
FDA
First approval
1961
Drug indication
diabetes mellitus
Non-insulin dependent diabetes
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
ABSORPTION
Readily absorbed following oral administration. Tolbutamide is detectable in plasma 30-60 minutes following oral administration of a single dose with peak plasma concentrations occurring within 3-5 hours. ; ; Absorption is unaltered if taken with food but is increased with high pH.
DESCRIPTION
A sulfonylurea family drug inhibiting sulfonylurea receptor 1 (ABCC8)/Kir6.2 ( KCNJ11).
(GtoPdb)
DESCRIPTION
Tolbutamide is an orally active KATP inhibitor. Tolbutamide inhibits cell proliferation, stimulates exocytosis of glucagon and reduces fetal lethality of mice. Tolbutamide can be used in the research of diabete[1][2][3][4].
PRICE
29
DESCRIPTION
Oral hypoglycemic agent; stimulates pancreatic islet cells to secrete insulin
(LOPAC library)
DESCRIPTION
Tolbutamide is an inhibitor of potassium channel, used for type II diabetes.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Tolbutamide is an oral antihyperglycemic agent. It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. It is used for treatment of NIDDM in conjunction with diet and exercise.
(Enamine Bioactive Compounds)
DESCRIPTION
Tolbutamide (HLS 831) is a sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
30
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Guide to Pharmacology
LOPAC library
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
56
Molecular Weight
270.1
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
1
Aromatic Ring Count
1
cLogP
1.78
TPSA
75.27
Fraction CSP3
0.42
Chiral centers
0.0
Largest ring
6.0
QED
0.8
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
Insulin
Pathway
Autophagy
Membrane Transporter/Ion Channel
Target
ABCC8, KCNJ1, KCNJ11, KCNJ8
Na+/K+ ATPase
Potassium Channel
Indication
diabetes mellitus
MOA
ATP channel blocker
Therapeutic Class
Hypoglycemic Agents
Source data
